Lemaitre Vascular (LMAT) EBITDA (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of EBITDA data on file, last reported at $17.8 million in Q1 2026.

• EBITDA for Q1 2026 came in at $17.8 million, up 40.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.9 million (up 64.92% YoY), and the FY2025 annual result was $15.8 million, up 32.19% from the prior year.
• EBITDA climbed to $17.8 million in Q1 2026 per LMAT's latest filing, from -$33.3 million in the prior quarter.
• Over five years, EBITDA peaked at $20.3 million in Q3 2025 and troughed at -$33.3 million in Q4 2025.
• A 5-year average of $6.4 million and a median of $9.5 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA soared 63.42% in 2023, then slumped 369.04% in 2024.
• A 5-year view of EBITDA shows it stood at $7.0 million in 2022, then soared by 46.49% to $10.2 million in 2023, then tumbled by 369.04% to -$27.5 million in 2024, then decreased by 21.24% to -$33.3 million in 2025, then soared by 153.39% to $17.8 million in 2026.
• Business Quant data shows LMAT's EBITDA at $17.8 million in Q1 2026, -$33.3 million in Q4 2025, and $20.3 million in Q3 2025.